You are here

Molecular Partners

A bad day for Molecular Partners

A bad day for Molecular Partners

EP Vantage

Molecular Partners

Flag link:

Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

Endpoints

Molecular Partners

clinical trials

Flag link:

Molecular Partners' Covid-19 therapy proves inactiv

Molecular Partners' Covid-19 therapy proves inactiv

EP Vantage

Molecular Partners

clinical trials

Flag link:

AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?

AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?

Endpoints

Molecular Partners

Flag link:

Another four IPOs complete busy week as biotech raise continues to match 2020's record pace

Another four IPOs complete busy week as biotech raise continues to match 2020's record pace

Endpoints

Lyell Immunopharma

Verve Therapeutics

Molecular Partners

ATAI Life Sciences

Century Therapeutics

Cyteir Therapeutics

Flag link:

Molecular Partners prices $64M IPO, falling short of original goal

Molecular Partners prices $64M IPO, falling short of original goal

Fierce Biotech

Molecular Partners

Flag link:

Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment

Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment

Biopharma Reporter

Molecular Partners

clinical trials

Flag link:

Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies

Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies

BioSpace

Molecular Partners

Flag link:

Novartis taps Molecular Partners for a new way to defeat COVID-19

Novartis taps Molecular Partners for a new way to defeat COVID-19

Fierce Biotech

Molecular Partners

Flag link:

FDA rejects AbbVie's eye drug, citing safety concerns

FDA rejects AbbVie's eye drug, citing safety concerns

BioPharma Dive

Molecular Partners

wet age-related macular degeneration

Flag link:

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Endpoints

wet age-related macular degeneration

Molecular Partners

Flag link:

Amgen pays $50M for Molecular Partners’ preclinical bispecific

Amgen pays $50M for Molecular Partners’ preclinical bispecific

Fierce Biotech

Molecular Partners

Flag link:

Roche backs out of its $1B cancer deal with Molecular Partners

Roche backs out of its $1B cancer deal with Molecular Partners

Fierce Biotech

Molecular Partners

Flag link:

Actavis keeps its Phase III promise with Molecular Partners' eye drug

Actavis keeps its Phase III promise with Molecular Partners' eye drug

Fierce Biotech

Molecular Partners

wet age-related macular degeneration

Flag link:

Roche teams with Molecular Partners on armed proteins in $1B-plus deal

Roche teams with Molecular Partners on armed proteins in $1B-plus deal

Fierce Biotech

Molecular Partners

Flag link:

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline

Fierce Biotech

Molecular Partners

Flag link:

Swiss Biotech IPOs May Revive Industry Starved of Investment

Swiss Biotech IPOs May Revive Industry Starved of Investment

Bloomberg

Molecular Partners

Flag link:

Allergan licenses retinal disease treatment from Molecular Partners in $420 million deal

Allergan licenses retinal disease treatment from Molecular Partners in $420 million deal

Yahoo/AP

Molecular Partners

retinal disease

Flag link: